2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient management
2018
Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers
Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncology 2018, 4: 1375-1381. PMID: 30027204, PMCID: PMC6233773, DOI: 10.1001/jamaoncol.2018.2487.Peer-Reviewed Original ResearchConceptsConventional cancer treatmentsUse of CMOverall survivalComplementary medicineHormone therapyTreatment delayCharlson-Deyo comorbidity scoreCancer treatmentCancer-accredited centersNational Cancer DatabaseCharacteristics of patientsYear of diagnosisRetrospective observational studyConventional cancer therapiesHigh refusal rateRace/ethnicityNonmetastatic breastComorbidity scorePatient characteristicsCurable cancerEntire cohortColorectal cancerCancer DatabaseInsurance typeObservational study